FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT (OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Ogden Christopher				2. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [CTMX]						elationship o ck all applica Director Officer (below)	able)	Person	10% Ow Other (sp below)	ner				
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400					3. Date of Earliest Transaction (Month/Day/Year) 08/10/2022							SVP, Finance and Accounting						
(Street) SOUTH S. FRANCIS	('A	9	4080	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(Sta		Zip)															
Date			ransaction e nth/Day/Ye	action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr	4. Securiti Disposed 5)	es Acquired (A) or (D) (Instr. 3, 4 and (A) or (D) Price		5. Amoun Securities Beneficia Owned Fe Reported Transacti (Instr. 3 a	5. Amount of Securities For Beneficially (D) Owned Following Reported Transaction(s) (Instr. 3 and 4)		Direct Indirect E	. Nature of ndirect leneficial lownership nstr. 4)				
(e.g., pt 1. Title of		., puts,	uts, calls, warrants, 4. Transaction Code (Instr. 5. Number of Derivative		Expiration Date of S (Month/Day/Year) Unit				8. Price of Derivative Security (Instr. 5) 8. Price of Derivative Security Security Beneficia Owned Followin Reporter Transact (Instr. 4)		ly C	0. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		, ,					
Stock Option (Right to Buy)	\$1.59	08/10/2022		A		82,500		(1)	08/09/2032	Common Stock	82,500	\$0.00	82,500		D			
Performance Stock Units (PSUs)	(2)	08/10/2022		A		13,750		(2)	(2)	Common Stock	13,750	\$0.00	13,750		D			

Explanation of Responses:

- 1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- 2. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

/s/ Lloyd Rowland, as Attorneyin-Fact for Christopher Ogden

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.